< Back to latest news & events

Event

Animal Microbiome Congress 2021

March 2021

Event date: 3rd March 2021

Animal Microbiome Congress will provide the latest clinical data and key content on the commercialisation of animal microbiome research. The global market is forecasted to grow to $9,775 million by 2028 due to demand for innovation from the rapidly growing meat and pet-healthcare industries.

The event supports smart interactions between business and academia to enable participants to capitalize on the growing global animal microbiome market.

HGF Partner Craig Thomson will be part of the panel discussion on Enacting a Commercially Successful Strategy for Animal Microbiome Globally on 3rd March. The panel will discuss:

  • Leveraging the various methodologies and technologies from human microbiome to animal to increase the value of the animal microbiome market
  • Understanding the spectrum of commercial opportunities in developing animal microbiome technology for the next decade around the world
  • Securing investment to launch a commercial animal microbiome product
  • Forming commercially successful partnerships with other animal and human microbiome companies by connecting the innovators with the implementers

Attendees

Latest updates

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

T 1847/22: Procedural considerations in appeal: Re-ordering of requests and the impact on admissibility

Background This case concerned EP 3 085 344 B1, which relates to a wound pad, a self-adhesive member comprising a wound pad. The patent was opposed by two opponents. During …

Read article

Regulation of NGT plants in Europe- Polish Presidency proposes an alternative solution to the Patent ban

In the latest development on the new proposed legislation for the regulation of NGT (gene-edited) plants in the EU, the Polish Presidency have proposed an amendment which removes the proposed …

Read article

T 0295/22: EPO Technical Board of Appeal relies on “bonus effect” case law to find Amgen’s patent to orally administered apremilast lacking in inventive step

This case concerned Amgen’s European patent no. 2962690 for apremilast, a drug sold under the brand name Otezla®, licensed for the treatment of e.g., psoriasis and psoriatic arthritis.  The patent …

Read article
Event - 18th March 2025

Salzburg Seminar: Pitfalls in trade mark practice - What can be protected as a trade mark?

The registration of trade marks is a central component of trade mark protection – but which signs can actually be protected? In recent years, the national trade mark offices and …

Event details

Can the Chancellor’s so-called “Europe’s Silicon Valley” really replicate the innovative activity of its namesake?

The Chancellor of the UK, Rachel Reeves, recently unveiled plans to deliver an Oxford-Cambridge growth corridor that promises to boost the UK economy by up to £78 billion by 2035.  …

Read article

UPC’s CFI (Milan) extends deadline to file defence to infringement claim to align with parallel EPO appeal proceedings

Dainese S.p.A. v. Alpinestars S.p.A. & ors. UPC_CFI_472/2024 – Milan Local Division (Perrotti, Zana, Klein, Ashley) – 15 January 2025 The Milan Local Division granted a defendant’s request for an …

Read article